Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
, , , , , , , and | Dec 21, 2019
About this article
Article Category: Original Article
Published Online: Dec 21, 2019
Page range: 31 - 36
DOI: https://doi.org/10.2478/bjmg-2019-0021
Keywords
© 2019 Popova-Labachevska M, Panovska-Stavridis I, Eftimov A, Kapedanovska Nestorovska A, Cevreska L, Ivanovski M, Ridova N, Trajkova S, Dimovski AJ, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Clinical and hematological findings in 17 JAK2V617F+PV patients in comparison withJAK2V617F allele burden.a
| Allele Burden (%) | <10.0% | 10.0-50.0% | >50.0% | ||||
|---|---|---|---|---|---|---|---|
| 4 (23.53) | 8 (47.06) | 5 (29.41) | |||||
| Age | 57.00±16.22 (47.10-66.89) | 58.00±18.41 (42.61-73.39) | 63.80±11.39 (49.66-77.94) | 0.496 | >0.05 | >0.05 | >0.05 |
| WBC (109/L) | 111.50(2.27-20.73±5.80 ) | (9.147.70±-10.571.72 ) | (8.744.65±-12.833.29 ) | 0.867 | >0.05 | >0.05 | >0.05 |
| RBC (1012/L) | 6.35(4.85±-0.94 7.85) | 6.41(5.64±-0.92 7.17) | (5.822.96±-2.30 8.68) | 0.956 | >0.05 | >0.05 | >0.05 |
| Hb (g/dL) | (20.2517.82±-15.26 22.68) | 18.52(16.80±-21.12 20.23) | 18.26(12.13±-49.34 24.39) | 0.523 | >0.05 | >0.05 | >0.05 |
| PCV (L/L) | 0.58(0.49±-0.05 0.07) | 0.56(0.53±-0.38 0.06) | (0.550.40±-0.01 0.07) | 0.921 | >0.05 | >0.05 | >0.05 |
| Platelets (109/L) | (295.00155.38±-434.6287.74 ) | (578.87371.92±-247.55 785.84) | (292.00160.98±-105.52 423.02) | 1.00 |
Clinical and hematological findings in 71 JAK2V617F+ET patients in comparison with JAK2V617F allele burden.a
| Allele Burden (%) | <10.0% | 10.0-50.0% | >50.0% | ||||
|---|---|---|---|---|---|---|---|
| 14 (19.718) | 50 (70.423) | 7 (9.859) | |||||
| Age | 59.75±14.76 (50.38-69.13) | 59.64±14.56 (55.50-63.78) | 61.14±18.13 (44.37-77.91) | 0.998 | >0.05 | >0.05 | >0.05 |
| WBC (109/L) | 8.08(6.98±-1.73 9.18) | (9.218.26±-10.163.35 ) | (6.2588.96±-2.93 11.67) | 0.631 | >0.05 | >0.05 | >0.05 |
| RBC (1012/L) | 4.43(4.02±-0.64 4.84) | 4.56(4.38±-0.63 4.74) | 4.84(3.85±-1.07 5.84) | 0.820 | >0.05 | >0.05 | >0.05 |
| Hb (g/dL) | (14.1713.23±-14.91 15.12) | (14.2613.89±-12.92 14.63) | 13.96(12.98±-10.88 14.99) | 0.925 | >0.05 | >0.05 | >0.05 |
| PCV (L/L) | 0.42(0.40±-0.04 0.05) | 0.43(0.42±-0.04 0.04) | 0.46(0.39±-0.0.0504 ) | 0.584 | >0.05 | >0.05 | >0.05 |
| Platelets (109/L) | (947.33767.98±-1126.68282.28 )( | 958.48872.86±-1044.09301.26 ) | (861.14652.78±-1069.50225.29 ) | 0.255 | >0.05 | >0.05 | >0.05 |
Clinical and hematological findings in 46 JAK2V617F+PMF patients in comparison with JAK2V617F allele burden.a
| Allele Burden (%) | <10.0% | 10.0-50.0% | >50.0% | ||||
|---|---|---|---|---|---|---|---|
| 3 (6.52) | 17 (36.96) | 26 (65.52) | |||||
| Age | 53.33±16.50 (12.34-94.33) | 60.59±14.31 (53.23-67.95) | 69.23±9.05 (65.574-72.887) | 0.427 | 0.078 | ||
| WBC (109/L) | (8.673.49±-13.842.08 ) | (12.768.34-±17.198.61 ) | (17.8914.07±-21.729.47 ) | 0.289 | |||
| RBC (1012/L) | 5.33(2.46±-1.15 8.20) | 5.64(4.88±-1.49 6.41) | (5.044.52±-1.28 5.55) | 0.399 | >0.05 | >0.05 | >0.05 |
| Hb (g/dL) | (15.0385.07±-26.27 21.56) | 16.95(11.53±-32.99 18.65) | 16.18(14.66±-37.00 17.71) | 0.369 | >0.05 | >0.05 | >0.05 |
| PCV (L/L) | 0.46(0.22±-0.00.079 ) | 0.52(0.47±-0.10 0.06) | (0.500.46±-0.10 0.05) | 0.373 | >0.05 | >0.05 | >0.05 |
| Platelets (109/L) | (707.67358.28±-1057.05140.65 ) | (777.71576.56±-391.21 978.85) | 781.42(676.73±-251.76 883.11) | 0.950 | >0.05 | >0.05 | >0.05 |
The JAK2V617F allele burden in 134 patients with different types of Ph-negative MPNs.
| Diagnosis | ET ( |
PV ( |
PMF ( |
p Value (Kruskal-Wallis test) | |||
|---|---|---|---|---|---|---|---|
| JAK2V617F allele burden Mean±SD (95% (CI) | 25.54±20.82 (20.61-30.46) | 34.65±27.39 (20.57-48.74) | 51.83±25.49 (44.26-59.40) | 0.000001 | <0.0001 | 0.3551 | 0.0258 |